T1	Participants 52 182	postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
T2	Participants 464 517	patients with hormone-receptor-positive breast cancer
T3	Participants 556 588	outpatient clinics and hospitals
T4	Participants 1362 1426	he study is registered at ClinicalTrials.gov, number NCT00626106
T5	Participants 590 744	We enrolled postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment.
T6	Participants 1437 1536	We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
T7	Participants 1752 1869	overall survival was worse in the the ganitumab group than in the placebo group (HR 1路78, 80% CI 1路27-2路50; p=0路025).
